Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that has a highly variable clinical course. Genomic features as zeta-chain-associated protein kinase 70 (ZAP70) expression and CD38 expression provide further differentiation of disease prognosis. Extensive studies have confirmed the oncogenic activities of IL-9 in lymphoma. The aim of the current study was to investigate the contribution of IL-9 expression to the pathogenesis of CLL and its correlation to other prognostic parameters. This study was conducted on 80 patients at diagnosis with CLL and 80 healthy controls. Using real time polymerase chain reaction and enzyme linked immunosorbant assay, IL-9 mRNA expression and its serum level were compared between patients and controls. They were both correlated with other prognostic factors. Results: There was an overexpression of IL-9 in CLL patients that correlated with modified Rai staging, ZAP70, CD38 and all hallmarks of an active and aggressive disease. The correlation between IL-9 upregulation and patient characteristics provided direct clinical evidence for its contribution to the pathogenesis of CLL. In conclusion, significantly higher expression of IL-9 measured at both the mRNA and the protein levels in patients with CLL that correlates with more complex course of the disease and worse prognosis may allow one to speculate its importance in the pathogenesis of the disease and its possible impact on prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815

    Article  CAS  PubMed  Google Scholar 

  2. Zenz T, Mertens D, Kuppers R, Döhner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37–50

    CAS  PubMed  Google Scholar 

  3. Simonsson B, Wibell L, Nilsson K (1980) β2-microglobulin in chronic lymphocytic leukaemia. Scand J Haematol 24:174–180

    Article  CAS  PubMed  Google Scholar 

  4. Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, Nazarov PV, Palissot V, Hood LE, Berchem G, Galas DJ (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 108:6573–6578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ, Oscier D (2005) ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90:1078–1088

    CAS  PubMed  Google Scholar 

  6. Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A, Dührsen U (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16:30–35

    Article  PubMed  Google Scholar 

  7. Van Bockstaele F, Pede V, Janssens A, Callewaert F, Offner F, Verhasselt B, Philippe J (2007) Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem 53:204–212

    Article  PubMed  Google Scholar 

  8. Zhu P, Degheidy HA, Marti GE, Li S, Abbasi F, Wiestner A, Amstutz P, Tang CM (2013) Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia. Leuk Lymphoma 54(3):579–586

    Article  CAS  PubMed  Google Scholar 

  9. Ritgen M, Lange A, Stilgenbauer S, Döhner H, Bretscher C, Bosse H, Stuhr A, Kneba M, Dreger P (2003) Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 101:2049–2053

    Article  CAS  PubMed  Google Scholar 

  10. Krober A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410–1416

    CAS  PubMed  Google Scholar 

  11. Demoulin J-B, Renauld J-C (1998) Interleukin 9 and its receptor: an overview of structure and function. Int Rev Immunol 16:345–364

    Article  CAS  PubMed  Google Scholar 

  12. Richard M, Grencis RK, Humphreys NE, Renauld J-C, Van Snick J (2000) Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci 97:767–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC (2009) Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 284:6773–6781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shang Y, Kakinuma S, Amasaki Y, Nishimura M, Kobayashi Y, Shimada Y (2008) Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas in vivo in susceptible B6 and resistant C3H mice. In Vivo 22:713–720

    CAS  PubMed  Google Scholar 

  15. Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E, Van Snick J (1992) Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci 89:5690–5694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kumar V (2014) Innate lymphoid cells: new paradigm in immunology of inflammation. Immunol Lett 157:23–37

    Article  CAS  PubMed  Google Scholar 

  17. Chen N, Lv X, Li P, Lu K, Wang X (2014) Role of high expression of IL-9 in prognosis of CLL. Int J Clin Exp Pathol 7:716–721

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Bittner C, Merz H, Krokowski M, Briese J, Wiedemann GJ, Feller AC (2000) New immunotherapeutic approaches for the treatment of anaplastic large cell lymphoma in a mouse model. Verh Dtsch Ges Pathol 84:187–198

    CAS  PubMed  Google Scholar 

  19. Jaffe ES, Harris NL, Stein H, Isaacson PG (2008) Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 112:4384–4399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM (2006) Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108:2407–2415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Feng LL, Gao JM, Li PP, Wang X (2011) IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-Hodgkin’s lymphoma. J Clin Immunol 31:1084–1094

    Article  CAS  PubMed  Google Scholar 

  22. Lv X, Feng L, Fang X, Jiang Y, Wang X (2013) Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 6:911–916

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundström C, Enblad G, Nilsson G (2003) Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin’s lymphoma. Leukemia 17:2513–2516

    Article  CAS  PubMed  Google Scholar 

  24. Kelleher K, Bean K, Clark SC, Leung WY, Yang-Feng TL, Chen JW, Lin PF, Luo W, Yang YC (1991) Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T cells. Blood 77:1436–1441

    CAS  PubMed  Google Scholar 

  25. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105–111

    Article  CAS  PubMed  Google Scholar 

  26. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Raj KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893–901

    Article  CAS  PubMed  Google Scholar 

  27. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Raj KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847

    CAS  PubMed  Google Scholar 

  28. Matrai Z (2005) CD38 as a prognostic marker in CLL. Hematology 10:39–46

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No funds were available for this study.

Author information

Authors and Affiliations

  1. Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Hadeer A. Abbassy & Reham A. Aboelwafa

  2. Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Omar M. Ghallab

Authors
  1. Hadeer A. Abbassy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reham A. Aboelwafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar M. Ghallab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hadeer A. Abbassy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abbassy, H.A., Aboelwafa, R.A. & Ghallab, O.M. Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients. Indian J Hematol Blood Transfus 33, 477–482 (2017). https://doi.org/10.1007/s12288-017-0804-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-017-0804-1

Keywords

Search

Navigation